Related references
Note: Only part of the references are listed.Differential sensitivity of A549 non-small cell lung carcinoma cell responses to epidermal growth factor receptor pathway inhibitors
Maria L. Jaramillo et al.
CANCER BIOLOGY & THERAPY (2008)
Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib
Tona M. Gilmer et al.
CANCER RESEARCH (2008)
Antineoplastic effect of rapamycin is potentiated by inhibition of IRS-1 signaling in prostate cancer cells xenografts
Josenilson C. Oliveira et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2008)
Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy
Julia D. Wulfkuhle et al.
JOURNAL OF PROTEOME RESEARCH (2008)
Stimulus design for model selection and validation in cell signaling
Joshua F. Apgar et al.
PLOS COMPUTATIONAL BIOLOGY (2008)
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer
Klarisa Rikova et al.
CELL (2007)
EGF receptor ubiquitination is not necessary for its internalization
Fangtian Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Epidermal growth factor receptors with tyrosine kinase domain mutations exhibit reduced Cbl association, poor ubiquitylation, and down-regulation but are efficiently internalized
David Padron et al.
CANCER RESEARCH (2007)
Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients
Trevor J. Pugh et al.
BMC CANCER (2007)
The needle in the haystack: Application of breast fine-needle aspirate samples to quantitative protein microarray technology
Amy Rapkiewicz et al.
CANCER CYTOPATHOLOGY (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib
Xuwan Liu et al.
EXPERIMENTAL CELL RESEARCH (2007)
Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival
Emanuel F. Petricoin et al.
CANCER RESEARCH (2007)
Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?
H. Uramoto et al.
BRITISH JOURNAL OF CANCER (2007)
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism
X. Wan et al.
ONCOGENE (2007)
Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification
Takafumi Okabe et al.
CANCER RESEARCH (2007)
Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation
Akiko Uchida et al.
CANCER SCIENCE (2007)
Src-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines
Jie Zhang et al.
AMERICAN JOURNAL OF PATHOLOGY (2007)
Comparison of three approaches for inhibiting insulin-like growth factor I receptor and their effects on NSCLC cell lines in vitro
Daria Cosaceanu et al.
GROWTH FACTORS (2007)
Laser capture microdissection technology
Virginia Espina et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2007)
Epidermal growth factor receptor mutations in lung cancer
Sreenath V. Sharma et al.
NATURE REVIEWS CANCER (2007)
Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations
Marianela Perez-Torres et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling
Susumu Kobayashi et al.
CANCER RESEARCH (2006)
Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib
Floriana Morgillo et al.
CANCER RESEARCH (2006)
Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation
Helene Blons et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2006)
Hypophosphorylation of residue Y1045 leads to defective Downregulation of EGFRvIII
Wei Han et al.
CANCER BIOLOGY & THERAPY (2006)
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib
David M. Jackman et al.
CLINICAL CANCER RESEARCH (2006)
EGF-ERBB signalling: towards the systems level
Ami Citri et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
A control theoretic paradigm for cell signaling networks: a simple complexity for a sensitive robustness
RP Araujo et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2006)
A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening
PA Jänne et al.
CLINICAL CANCER RESEARCH (2006)
Laser-capture microdissection
Virginia Espina et al.
NATURE PROTOCOLS (2006)
Dynamic profiling of the post-translational modifications and interaction partners of epidermal growth factor receptor signaling after stimulation by epidermal growth factor using extended range proteomic analysis (ERPA)
Shiaw-Lin Wu et al.
MOLECULAR & CELLULAR PROTEOMICS (2006)
Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy
F. Ciardiello et al.
ANNALS OF ONCOLOGY (2006)
Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer
T Takano et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Proteomic analysis of apoptotic pathways reveals prognostic factors in follicular lymphoma
C Gulmann et al.
CLINICAL CANCER RESEARCH (2005)
Supra-additive growth inhibition by a celecoxib analogue and carboxyamido-triazole is primarily mediated through apoptosis
ME Winters et al.
CANCER RESEARCH (2005)
ERBB receptors and cancer: The complexity of targeted inhibitors
NE Hynes et al.
NATURE REVIEWS CANCER (2005)
Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer
SH Yang et al.
CLINICAL CANCER RESEARCH (2005)
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
H Shigematsu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Positive and negative regulation of insulin signaling through IRS-1 phosphorylation
P Gual et al.
BIOCHIMIE (2005)
Specificity in signal transduction: From phosphotyrosine-SH2 domain interactions to complex cellular systems
T Pawson
CELL (2004)
EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib
W Pao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways
R Sordella et al.
SCIENCE (2004)
Identification of 14-3-3ζ as an EGF receptor interacting protein
MP Oksvold et al.
FEBS LETTERS (2004)
Common and distinct elements in cellular signaling via EGF and FGF receptors
J Schlessinger
SCIENCE (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
The docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI-3K/Akt cell survival pathway
Dawn R. Mattoon et al.
BMC BIOLOGY (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Constitutive EGFR signaling confers a motile phenotype to neural stem cells
JA Boockvar et al.
MOLECULAR AND CELLULAR NEUROSCIENCE (2003)
Serine mutations that abrogate ligand-induced ubiquitination and internalization of the EGF receptor do not affect c-Cbl association with the receptor
MP Oksvold et al.
ONCOGENE (2003)
An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors
AW Burgess et al.
MOLECULAR CELL (2003)
Assembly of cell regulatory systems through protein interaction domains
T Pawson et al.
SCIENCE (2003)
Sustained loss of a neoplastic phenotype by brief inactivation of MYC
M Jain et al.
SCIENCE (2002)
TGF-β signaling:: positive and negative effects on tumorigenesis
LM Wakefield et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2002)
SH2 domains, interaction modules and cellular wiring
T Pawson et al.
TRENDS IN CELL BIOLOGY (2001)
TGF-β signaling in tumor suppression and cancer progression
R Derynck et al.
NATURE GENETICS (2001)
Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front
CP Paweletz et al.
ONCOGENE (2001)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
The ErbB signaling network: receptor heterodimerization in development and cancer
MA Olayioye et al.
EMBO JOURNAL (2000)
Share Paper
